timolumab (BTT1023) / Acorda - LARVOL DELTA

Vascular adhesion protein-1 blockade in primary sclerosing cholangitis: Open-label, multicenter, single-arm, phase II trial. (PubMed, Hepatol Commun) - "The BUTEO trial confirmed 8 mg/kg timolumab had no short-term safety signals and resulted in sufficient circulating levels of VAP-1 blocking timolumab. However, the trial was stopped after an interim assessment due to a lack of efficacy as determined by no significant change in serum liver tests."

Journal • P2 data • P2 data • Fibrosis • Hepatology • Immunology • Inflammation • Liver Cirrhosis • AOC3

Biotie to acquire Newron creating a leading European biopharmaceutical company focused on central nervous system drug development (Biotie) - Biotie Therapies & Newron Pharma announced that they have signed an agreement for Biotie to acquire Newron in a transaction valued at €45M; BTT-1023 has completed two P1b studies in RA & psoriasis & Biotie expects to start proof-of-concept clinical studies in selected indications in H2 2012; Biotie has licensed the rights to develop & commercialize its VAP-1 antibody in Japan, Taiwan, Singapore, New Zealand & Australia to Seikagaku Corporation

Anticipated PoC study initiation • Merger & acquisition • Pipeline update • Psoriasis • Rheumatoid Arthritis

Biotie Therapies: Jefferies Global Healthcare Conference (Biotie) - Anticipated partnership in 2013 or after

Anticipated licensing / partnership • Psoriasis

Biotie Therapies: Annual Report 2015 (Biotie) - Anticipated expiry of composition of matter patents in US, Australia, China, South Korea, Russia, New Zealand, Singapore, Ukraine and South Africa in 2028; Anticipated expiry of method of use patent in 2030

Anticipated patent expiry • Psoriasis

BUTEO: A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis (clinicaltrials.gov) - P2; N=23; Completed; Sponsor: University of Birmingham; Recruiting ➔ Completed; N=41 ➔ 23; Trial completion date: Mar 2019 ➔ Oct 2018

Enrollment change • Trial completion • Trial completion date